

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



✓ 03C0

In re Applicant:

Tony PELED, et al

Serial No.: 09/988,127

Filed: November 19, 2001

Group Art Unit: 1644

For: METHODS OF CONTROLLING...

Attorney
Docket: 00/21438

Examiner:

Director of the Patent and Trademark Office

Washington, D.C. 20231

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Sir:

This is in response to the United States Patent and Trademark Office Action mailed December 6, 2001, which response is being made on or before February 6, 2002, and for which no extension fee is due.

By said Action, the drawing sheets were deemed as not having the appropriate margins. By this response, Applicant is submitting 22 new formal drawing sheets to correct the informality noted by the Application Branch, along with the Notice to File Corrected Application Papers.

Moreover, Applicant is submitting herewith the Abstract on a separate page as originally filed with the PCT Application, together with an extra copy of Figures 27e and 27f, which also formed part of the filing in the U.S. when the PCT application was filed designating the U.S.

Respectfully submitted,

Sol Sheinbein
Attorney for Applicant
Registration No. 25,457

Date: January 27, 2002



#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Tony Peled et al.

Serial No.: 09/988,127

Filed: November 19, 2001

Group Art Unit: NA

For: METHODS OF CONTROLLING
PROLIFERATION AND
DIFFERENTIATION OF
STEM AND PROGENITOR CELLS

§

Attorney
Docket: 01/21438

Examiner:

§

Commissioner of Patents and Trademarks
Washington, D.C. 20231

RESPONSE TO COMMUNICATION

Dear Sir:

This is a response to a notice to file corrected application papers and, in particular, to comply with requirements for patent applications containing nucleotide and/or amino acid sequence disclosures, sent December 6, 2001, a response to which is due, and being made, within two months. Please amend the above-identified application as follows:

In the Specification:

Please replace the Sequence Listing on pages 58, with that attached herewith.

REMARKS

Enclosed please find:

- (i) a nucleotide and/or amino acid listing in a computer readable and paper forms; and
- (ii) a copy of the Notice.

Statements

The content of the paper and computer readable form are the same and include no new matter.

Respectfully submitted,



Sol Sheinbein
Attorney for Applicant
Registration No. 25,457

Date: December 31, 2001.

Encl.:

a nucleotide and/or amino acid listing in a computer readable form; and
a copy of the Notice.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/988,127	11/19/2001	Tony Peled	00/21438

CONFIRMATION NO. 8221

FORMALITIES LETTER



OC000000007165800

G. E. EHRLICH (1995) LTD.
c/o ANTHONY CASTORINA
SUITE 207
2001 JEFFERSON DAVIS HIGHWAY
ARLINGTON, VA 22202



Date Mailed: 12/06/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu

of a new CRF.

For questions regarding compliance to these requirements, please contact:

O I P E
JAN 29 2002
U. S. PATENT & TRADEMARK OFFICE
USPTO

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

The following item(s) appear to have been omitted from the application:

- Figure(s) 27e and 27f described in the specification.

I. Should applicant contend that the above-noted omitted item(s) was in fact deposited in the U.S. Patent and Trademark Office (USPTO) with the nonprovisional application papers, a copy of this Notice and a petition (and \$130.00 petition fee (37 CFR 1.17(h))) with evidence of such deposit **must** be filed within **TWO MONTHS** of the date of this Notice. The petition fee will be refunded if it is determined that the item(s) was received by the USPTO.

II. Should applicant desire to supply the omitted item(s) and accept the date that such omitted item(s) was filed in the USPTO as the filing date of the above-identified application, a copy of this Notice, the omitted item(s) (with a supplemental oath or declaration in compliance with 37 CFR 1.63 and 1.64 referring to such items), and a petition under 37 CFR 1.182 (with the \$130.00 petition fee (37 CFR 1.17(h))) requesting the later filing date **must** be filed within **TWO MONTHS** of the date of this Notice.

III. The failure to file a petition (and petition fee) under the above options (I) or (II) within **TWO MONTHS** of the date of this Notice (37 CFR 1.181(f)) will be treated as a constructive acceptance by the applicant of the application as deposited in the USPTO. **THIS TWO MONTH PERIOD IS NOT EXTENDABLE UNDER 37 CFR 1.136(a) or (b).** In the absence of a timely filed petition in reply to this Notice, the application will maintain a filing date as of the date of deposit of the application papers in the USPTO, and original application papers (i.e., the original disclosure of the invention) will include only those application papers present in the USPTO on the date of deposit.

In the event that applicant elects not to take action pursuant to options (I) or (II) above (thereby constructively electing option (III)), amendment of the specification to renumber the pages consecutively and cancel incomplete sentences caused by any omitted page(s), and/or amendment of the specification to cancel all references to any omitted drawing(s), relabel the drawing figures to be numbered consecutively (if necessary), and correct the references in the specification to the drawing figures to correspond with any relabelled drawing figures, is required. Any drawing changes should be accompanied by a copy of the drawing figures showing the proposed changes in red ink. Such amendment and/or correction to the drawing figures, if necessary, should be by way of preliminary amendment submitted prior to the first Office action to avoid delays in the prosecution of the application.

*A copy of this notice **MUST** be returned with the reply.*

Mar

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE